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Objectives The aim of this study is to assess the serial changes in strut apposition and coverage of
the bioresorbable vascular scaffolds (BVS) and to relate this with the presence of intraluminal
masses at 6 months with optical coherence tomography (OCT).
Background Incomplete strut/scaffold apposition (ISA) and uncovered struts are related to a higher
risk of scaffold thrombosis. Bioresorbable vascular scaffolds can potentially avoid the risk of scaffold
thrombosis because of its complete resorption. However, during the resorption period, the risk of
scaffold thrombosis is unknown.
Methods OCT was performed in 25 patients at baseline and 6 months. Struts were classiﬁed according to
apposition, coverage, and presence of intraluminal masses. Persistent ISA was deﬁned as malapposed struts
present at baseline and follow-up, and late acquired ISA as ISA developing at follow-up, and scaffold pattern
irregularities when the strut distribution suggested scaffold fracture.
Results At baseline, 3,686 struts were analyzed: 128 (4%) were ISA, and 53 (1%) were located over side-
branches (SB). At 6 months, 3,905 struts were analyzed: 32 (1%) ISA, and 35 (1%) at the SB. Persistent ISA was
observed more frequently than late acquired-ISA (81% vs. 16%, respectively; 3% were unmatchable). Late ac-
quired ISA was associated with scaffold pattern irregularities, which were related to overstretching of the scaf-
fold. Uncovered struts (63 struts, 2%) were more frequently observed in ISA and SB struts, compared with ap-
posed struts (29% vs. 1%; p  0.01). Intraluminal masses (14 cross-sections, 3%; in 6 patients, 24%) were more
frequently located at the site of ISA and/or uncovered struts (39% vs. 2% and 13% vs. 2%, respectively;
p  0.01).
Conclusions The lack of strut apposition at baseline is related to the presence of uncovered struts and in-
traluminal masses at 6 month. An appropriate balloon/artery ratio respecting the actual vessel size and avoid-
ing the overstretching of the scaffold can potentially decrease the risk of scaffold thrombosis. (ABSORB Clinical
Investigation, Cohort B [ABSORB B]; NCT00856856) (J Am Coll Cardiol Intv 2011;4:992–1001) © 2011 by the
American College of Cardiology Foundation
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993Serial intravascular ultrasound (IVUS) imaging of metallic
drug-eluting stents (DES) has shown that incomplete
stent/strut apposition (ISA) at follow-up can be caused by
the persistence of ISA observed at baseline or by the new
appearance of late acquired incomplete scaffold/strut appo-
sition (LAISA) (1,2). Recent reports suggest that strut
apposition is important for the development of strut cover-
age, because malapposed struts are more frequently uncov-
ered at follow-up, as compared with apposed struts (3,4).
Furthermore, the absence of neointimal coverage as well as
the presence of malapposed struts have been related to late
stent thrombosis, even in patients treated with dual anti-
platelet therapy (5,6).
The novel everolimus-eluting bioresorbable vascular
scaffolds (BVS) are promising intravascular devices that
can potentially circumvent the risk of malapposed and
uncovered struts at follow-up. Notably, at 2 years after
implantation, the polymeric material has been shown
to be resorbed with the disappearance of struts that were
initially malapposed or at side branches (SBs) (7). The
first-generation BVS (version 1.0) demonstrated a high
rate of malapposed struts before complete resorption,
with a rate of malapposed struts at 6 months higher than
at baseline (6% vs. 5%, respectively; p  0.01). This
ncommon phenomenon was caused by a low rate of
esolved malapposed struts and by the occurrence of
AISA at 6-month follow-up (8). The late scaffold area
eduction (shrinkage) observed at 6 months was the most
lausible explanation for the higher rate of ISA obser-
ed at follow-up compared with baseline. Despite this,
nly 1% of struts remained uncovered at 6-month
ollow-up (8).
The new-generation BVS (version 1.1) uses a new platform
esign and a different processing of the polymer, as compared
ith the previous generation of BVS (version 1.0), resulting in
n increased radial force and longer retention of mechanical
ntegrity (9). Consequently, there is now no detectable loss in
caffold area at 6 months (10,11). Nevertheless, ISA and
ncovered struts can still be detected with the new generation
f BVS, but the fate of these struts is unknown.
The aim of our study is to describe the serial changes of
SA and uncovered struts at baseline and at 6-month
ollow-up of the new generation of BVS (version 1.1), as
ssessed by optical coherence tomography (OCT).
Cohort B study has been funded by Abbott Vascular (Santa Clara, California). Dr. Windecker
has received research grants from Abbott, Cordis, Medtronic, Biosensors, and Boston
Scientific. Dr. Dudek has received research grants or served as consultant/advisory board
member for Abbott, Adamed, AstraZeneca, Biotronik, Balton, Bayer, BBraun, BioMatrix,
Boston Scientific, Boehringer Ingelheim, Bristol-Myers Squibb, Cordis, Cook, Eli Lilly,
EuroCor, Glaxo, Invatec, Medtronic, The Medicines Co., MSD, Nycomed, Orbus-Neich,
Pfizer, Possis, Promed, Sanofi-Aventis, Siemens, Solvay, Terumo, and Tyco. Dr. Smits has 2Methods
Population. The ABSORB Cohort B (A Clinical Evalua-
ion of the Bioabsorbable Everolimus Eluting Coronary
tent System [BVS EECSS] in the Treatment of Patients
ith de Novo Native Coronary Artery Lesions) trial is a
onrandomized, multicenter, single-arm, efficacy-safety
tudy (12). The study included 101 patients that were
llocated to 6-month angiographic and intravascular imag-
ng control (cohort B1) or 12-month angiographic and
ntravascular imaging control (cohort B2). All lesions were
reated with a single-size device (3  18 mm) of the new
eneration of BVS (version 1.1). The OCT imaging was an
ptional investigation performed in selected participating
enters. In brief, the common inclusion criteria were pa-
ients 18 years of age or older, with a diagnosis of stable,
nstable, or silent ischemia that presented with a de novo
esion in a native coronary artery between 50% and 99% of
he luminal diameter and a Thrombolysis In Myocardial
nfarction flow grade of 1 or
ore. Exclusion criteria in-
luded patients with an evolving
yocardial infarction, stenosis
f the left main or ostial right
oronary artery, presence of in-
racoronary thrombus, or heavy
alcification.
The present study is a post
oc analysis of those patients
ncluded in the ABSORB co-
ort B1 that were serially im-
ged with OCT at baseline and
t 6-month follow-up.
BVS. The BVS version 1.1 revi-
ion is a balloon-expandable de-
ice, consisting of a polymer
ackbone of poly-L-lactide coated with a thin layer of a 1:1
mixture of an amorphous matrix of poly-D,L-lactide polymer
containing 100 g/cm2 of the antiproliferative drug everoli-
us. The implant is radiolucent but has 2 platinum markers
t each edge, which allows visualization on angiography and
ther imaging modalities. Physically, the scaffold has struts
ith an approximate thickness of 150 m arranged as
n-phase zigzag hoops linked together by 3 longitudinal
ridges.
eceived travel fees from Abbott Vascular. Ms. Susan Veldhof and Dr. Rapoza are
mployees of Abbott Vascular. Dr. Ormiston is on the advisory board of and has
eceived minor honoraria from Abbott Vascular and Boston Scientific. All other
uthors have reported that they have no relationships relevant to the contents of
his paper to disclose.
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Abbreviations
and Acronyms
BVS  bioresorbable
vascular scaffolds
DES  drug-eluting stents
ISA  incomplete scaffold/
strut apposition
IVUS  intravascular
ultrasound
LAISA  late acquired
incomplete scaffold/
strut apposition
OCT  optical coherence
tomography
SB  side branch011, accepted March 28, 2011.
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994Treatment procedure. Lesions were treated with routine
interventional techniques. As per protocol, pre-dilation with
conventional balloons was mandatory. Pre-dilation balloons
should be shorter than the length of the scaffold and
0.5-mm smaller in diameter than the reference vessel. The
BVS implantation should not exceed the burst pressure as
indicated by the product chart (16 atm). Post-dilation with
a balloon shorter than the implanted device was allowed at
the discretion of the operator but, when performed, should
only be done with balloons sized to fit within the boundaries
of the scaffold. Intravascular imaging techniques were per-
formed when optimal BVS placement was obtained accord-
ing to the judgment of the physician on the basis of
angiographic results. In case of suboptimal deployment as
assessed by intravascular imaging techniques, post-dilations
were allowed at discretion of the operator until optimal stent
placement was achieved (on the basis of angiography). After
the last post-dilation, a new intravascular imaging acquisi-
tion was performed and was used for the study analysis.
OCT acquisition. The OCT imaging was performed with 2
different OCT systems (M3 Time-Domain System and
C7XR Fourier-Domain System; LightLab Imaging, West-
ford, Massachusetts). The M3 OCT system used a standard
intracoronary guidewire to cross the target lesion, and then
a single-lumen (e.g., Transit, Cordis, Johnson and Johnson,
Miami, Florida, or ProGreat, Terumo, Tokyo, Japan) or
double-lumen catheter (0.023-inch TwinPass, Vascular So-
lutions, Inc., Minneapolis, Minnesota) was required to
exchange the conventional wire with the LightLab Imaging
ImageWire. Pullback was performed during continuous
injection of contrast medium (1 to 3 ml/s, iodixanol 370;
Visipaque, GE Healthcare, Cork, Ireland) through the
guide catheter with an injection pump. The automated
pullback was performed at 3 mm/s with a frame rate of 20
images/s.
The C7XR system used a conventional wire to cross the
segment of interest. The OCT imaging catheter (Dragon-
fly, LightLab Imaging) was then advanced distally to the
treated region. Pullback was performed during continuous
injection of contrast medium (3 ml/s, iodixanol 370; Visi-
paque) through the guide catheter with an injection pump.
The automated pullback rate was 20 mm/s, and the frame
rate was 100 images/s.
OCT analysis. Offline OCT qualitative data analysis was car-
ried out by 2 expert analysts with the proprietary software for
offline analysis (LightLab Imaging). Both investigators were
blinded to the patient, procedural, and clinical characteristics as
well as to the clinical outcomes. Adjusting for the pullback
speed, the analysis of contiguous cross-sections was performed
at 1-mm longitudinal intervals within the treated segment (7
cross-sections/mm in case of M3 OCT system and 5 cross-
sections/mm in case of C7 OCT system).
At baseline, embedded struts were defined as present
when more than one-half thickness of the strut was im- Cpacted into the vessel wall; protruding struts were defined as
struts being in contact with the vessel wall but with less than
one-half strut thickness impacted into the vessel wall. Both
embedded and protruding struts presented with different
degrees of apposed struts at follow-up, but we made no
distinction. At baseline and follow-up, malapposed struts
were defined as struts where the abluminal surfaces were
separated from the vessel wall by flush; and SB struts were
defined as struts overlying the ostium of an SB (Fig. 1). It
is noteworthy that, in contrast with metallic stents, the BVS
allows the assessment of the structures located behind the
struts without the usual shadowing of metallic struts.
Therefore, strut malapposition can be easily assessed when
the polymeric strut is separated from the vessel wall. At
follow-up, the absence of strut coverage was defined when 1
of the strut corners preserved the right angle shape without
signs of neointimal tissue (Fig. 1). Although strut apposi-
tion and coverage was measured as a consensus between 2
analysts, a total of 100 random images of 10 different
patients were analyzed separately by 2 analysts to ensure the
agreement of the qualitative assessments. Scaffold pattern
irregularities were defined when struts were found in loca-
tions incongruent with the scaffold pattern. They were
classified into 2 categories: 1) 2 struts overhanging each
other in the same angular sector of the lumen perimeter,
with or without malapposition; and/or 2) isolated struts
located more or less at the center of the vessel without
obvious connection to the expected adjacent strut pattern.
At follow-up, protruding masses attached to the vessel wall
or floating masses without contact with the vessel wall have
been suggested to be thrombi (3). However, the distinction
between thrombi and neointimal protrusions into the lumen
is not always possible. Therefore, any irregular mass at-
tached to the polymeric struts or floating into the lumen has
been classified as intraluminal mass without distinction
between thrombus and neointima.
With clear landmarks in the longitudinal OCT images,
all cross-sections with at least 1 ISA or SB strut at baseline
were matched with the corresponding image of all the
possible cross-sections of the entire recording at follow-up
(every 7 cross-sections/mm in case of M3 OCT system and
every 5 cross-sections/mm in case of C7 OCT system).
Every single ISA or SB strut at baseline was investigated at
follow-up, to assess its apposition and the state of neointi-
mal coverage. Similarly, those images with at least 1 ISA
and/or uncovered struts at follow-up were matched to the
corresponding image at baseline of all possible cross-
sections of the entire recording at baseline and investigated
to assess the original state of strut apposition.
Statistical analysis. Statistical analysis was performed with
he SPSS software (version 15.0, SPSS, Inc., Chicago,
llinois). Discrete variables are presented as counts and
ercentages and continuous variables as mean  SD.
omparisons of continuous variables between baseline and
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995follow-up have been estimated with the nonparametric
Wilcoxon signed-rank test. Comparison of percentages of
uncovered struts between apposed and nonapposed struts
has been performed with the Mann-Whitney U test at strut
level analysis. Adjustments for clustering data at the patient
and frame level analysis have not been performed. A 2-sided
p value 0.05 was considered statistically significant.
The interobserver agreement for qualitative measure-
ments was quantified by the Cohen’s kappa test for concor-
dance (13). In accordance with previous publications, a
value0 indicates poor agreement, 0 to 0.20 indicates slight
agreement, 0.21 to 0.40 indicates fair agreement, 0.41 to
0.60 indicates moderate agreement, 0.61 to 0.80 indicates
good agreement, and 0.81 to 1.0 indicates excellent agree-
ment (14).
Results
Population. The ABSORB Cohort B1 study included 45
atients, 28 of whom were imaged with OCT at baseline.
wo patients were excluded due to suboptimal quality of the
CT recording (lack of imaging of the full length and/or
erimeter of the implant); and 1 asymptomatic patient
ithdrew consent to invasive control at 6-month follow-up.
he remaining 25 patients, all of whom were serially imaged
ith OCT at baseline and 6-month follow-up, were in-
luded in the present study. A total of 11 and 9 patients
Figure 1. Strut Apposition and Coverage Assessment
Apposition assessment at baseline: (A) protruding struts: less than one-half thi
one-half thickness of the strut is impacted into the vessel wall; (C) incomplete
sel wall; (D) side-branches (SB) strut: the strut is located in the take-off of an S
up: (E) apposed and covered strut: the 4 corners of the polymeric strut have l
uncovered strut: 1 of the 2 endoluminal strut corners preserves the right angl
corners have lost the right angle shape with signs of tissue coverage; (H) ISA/
signs of tissue coverage.ere imaged with the M3 OCT system at baseline andollow-up, respectively; whereas 14 and 16 patients were
maged with the C7 OCT system at baseline and follow-up,
espectively. Only 2 patients were imaged with different
CT systems at baseline and follow-up.
Table 1. Baseline Clinical and Angiographic Characteristics (n  25)
Male 20 (80.0)
Age (yrs) 62.4 10.0
Hypertension 14 (56.0)
Hypercholesterolemia 24 (96.0)
Diabetes 2 (8.0)
Smokers 5 (20.0)
Prior MI 11 (44.0)
Prior PCI 6 (24.0)
Clinical indication
Stable angina 21 (84.0)
Unstable angina 4 (16.0)
Number of vessel disease
1 21 (84.0)
2 3 (12.0)
3 1 (4.0)
Target vessel
Left anterior descending 11 (44.0)
Left circumﬂex 6 (24.0)
Right coronary artery 8 (32.0)
Values are count (%) or mean SD.
s of the strut is impacted into the vessel wall; (B) embedded strut: more than
scaffold apposition (ISA): the back-side of the strut is separated from the ves-
out any contact with the vessel wall. Strut coverage assessment at follow-
right angle shape with signs of tissue coverage; (F) apposed and
e without signs of tissue coverage; (G) ISA/SB and covered strut: the 4 strut
uncovered: 1 of the 4 strut corners preserves the right angle shape withoutcknes
strut/
B with
ost the
e shap
SB andMImyocardial infarction; PCI percutaneous coronary intervention.
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996Baseline clinical and angiographic characteristics are
shown in Table 1. Mean age was 62.4 years; 80% were men,
nd 8% were diabetic. The clinical indication of the index
rocedure was stable angina in 84% of patients. A total of
5% of patients had single-vessel disease.
Qualitative OCT ﬁndings at baseline. Qualitative OCT find-
ings at baseline are shown in Table 2. At baseline, 3,686
struts in 424 frames were analyzed: 2,554 were classified as
Table 2. Qualitative OCT Findings at Baseline (n  25)
Number of struts 3,686
Protruding 2,554 (69.3%)
Embedded 951 (25.8%)
ISA 128 (3.5%)
SB 53 (1.4%)
Matched ISA at baseline that at 6 months became 128
Apposed  covered 97 (75.8%)
Apposed  uncovered 6 (4.7%)
Persistent ISA  covered 15 (11.7%)
Persistent ISA  uncovered 4 (3.1%)
Unmatchable 6 (4.7%)
Matched SB struts at baseline that at 6 months became 53
Apposed  covered 12 (22.7%)
Apposed  uncovered 1 (1.9%)
SB  covered 27 (50.9%)
SB  uncovered 5 (9.4%)
Unmatchable 8 (15.1%)
ISA incomplete scaffold/strut apposition; OCT optical coherence tomography;
SB side branch.
Figure 2. Distribution of Malapposed and Uncovered Struts
Strut distribution with respect to the optical coherence tomography (OCT) cat
length (from distal to proximal) of malapposed, side-branch (SB), and uncovered struprotruding (69.3%), 951 as embedded (25.8%), 128 as ISA
(3.5%), and 53 struts were overlying an SB (1.4%). Figure 2
shows the distribution of malapposed and SB struts
throughout the length of the BVS.
Matched cross-sections. A total of 80 of 90 baseline images
with ISA and/or SB struts were properly matched with the
corresponding frame at 6-month follow-up. Therefore,
95.3% of malapposed and 84.9% of SB struts were properly
matched between time points. At follow-up, the fate of the
malapposed struts observed at baseline was: 80.5% resolved
into apposed struts, and 14.8% persisted as ISA (4.7% were
unmatchable).
Qualitative OCT ﬁndings at 6-month follow-up. At 6
months, all polymeric struts were visible, remaining with the
preserved box appearance. Qualitative OCT findings are
shown in Table 3. At follow-up, 3,905 struts in 433 frames
were analyzed: 3,838 were apposed (98.3%), 32 were malap-
posed (0.8%), and 35 were located over an SB (0.9%). Lack
of tissue coverage was detected in 63 struts (1.6%). Distri-
bution of ISA, SB, and uncovered struts throughout the
length of the BVS is shown in Figure 2.
Strut coverage. A total of 43 of 3,838 apposed struts (1.1%)
were uncovered, whereas 10 of 32 ISA struts (31.3%) and 10
of 35 SB struts (28.6%) were uncovered. The comparison of
the rate of uncovered plus apposed struts (1.1%) with the
rate of uncovered plus ISA or SB struts (29.0%) was
statistically significant (p  0.01) (Fig. 3).
Intraluminal masses. At 6 months, intraluminal masses were
observed in 14 cross-sections (2.9%) in 6 patients (24.0%).
(degrees) and location throughout the bioresorbable vascular scaffold (BVS)heter
ts. ISA  incomplete strut/scaffold apposition.
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997Notably, intraluminal masses were more often associated with
malapposed and/or uncovered struts rather than apposed and
covered struts. Of struts with attached intraluminal masses, 40.0%
of struts were malapposed and uncovered, 18.2% were malap-
posed and covered, 9.3% were apposed and uncovered, and 0.9%
were apposed and covered (p  0.01).
Matched cross-sections. A total of 51 of 53 cross-sections
ith ISA or uncovered struts were properly matched with
he corresponding image at baseline. Likewise, 97.1% of
alapposed and 95.2% of uncovered struts were properly
atched. The ISA was more frequently caused by persistent
SA (81.3%) rather than LAISA (15.6%); 3.1% of the struts
ere unmatchable. Late acquired ISA was only found in 2
atients (8.0%). Serial analysis of uncovered struts showed
hat, at baseline, 36 matched struts were classified as
rotruding (57.1%), 4 as embedded (6.3%), and 10 as ISA
15.9%), and 10 struts were overlying an SB (15.9%); 4.8%
ere unmatchable.
Clinical outcomes. At 6-month follow-up, no death, spon-
taneous acute myocardial infarction, scaffold thrombosis, or
target lesion revascularization of the 25 patients included in
Table 3. Qualitative OCT Findings at 6-Month Follow-Up
Number of struts at 6 months 3,905
Apposed  covered 3,795 (97.2%)
Apposed  uncovered 43 (1.1%)
ISA  covered 22 (0.5%)
ISA  uncovered 10 (0.3%)
SB  covered 25 (0.6%)
SB  uncovered 10 (0.3%)
Number of struts with attached intraluminal masses at 6 months* 21 (0.5%)
Apposed  covered 9 (0.2%)
Apposed  uncovered 4 (9.3%)
ISA  covered 4 (18.2%)
ISA  uncovered 4 (40%)
SB  covered 0
SB  uncovered 0
Matched ISA struts at follow-up that at baseline were: 32 (0.8%)
ISA 26 (81.3%)
Protruding 5 (15.6%)
Embedded 0
Unmatchable 1 (3.1%)
Matched uncovered struts at follow-up that at baseline were: 63 (1.6%)
Protruding 36 (57.1%)
Embedded 4 (6.3%)
ISA 10 (15.9%)
SB 10 (15.9%)
Unmatchable 3 (4.8%)
Matched ISA  uncovered struts at follow-up that at baseline were: 10 (0.3%)
Protruding 5 (50.0%)
ISA 5 (50.0%)
N 25. *Percentages are estimated according the total amount of each strut type.
Abbreviations as in Table 2.the present study were documented. One patient experi-enced a periprocedural acute myocardial infarction at the
time of the index procedure without any further complica-
tions. Another patient with suboptimal OCT imaging at
baseline (and excluded from our study) presented with
nonclinically driven target lesion revascularization at day 33.
At that time, OCT imaging showed scaffold pattern irreg-
ularities demonstrating substantial structural distortion,
with intraluminal masses attached to the malapposed struts.
At the time of the index procedure, this patient was also
treated with a post-dilation balloon that achieved a larger
predicted diameter than the maximum limit recommended
for the BVS.
Qualitative coverage agreement between the 2 analysts.
Two analysts investigated, in separate analyses, 100
selected cross-sections of 10 different patients with 767
struts. Both analysts agreed in 710 and 35 covered and
uncovered struts, respectively. The Kappa index was 0.75
(good agreement).
Discussion
The main findings of our study are: 1) with the BVS version
1.1, the number of malapposed struts decreased from
baseline to 6-month follow-up; 2) 80% of the malapposed
struts observed at baseline resolved into apposed struts at
follow-up, with a relatively low rate of LAISA at 6 months;
3) as at baseline and follow-up, ISA and SB struts were
associated with a lack of strut coverage at 6 months; and
4) intraluminal masses were rarely observed but were more
frequently associated with ISA and uncovered struts.
Acute ISA. With metallic-DES, acute ISA ranged from
.7% to 11.6% of the total amount of struts in patients
ithout ST-segment elevation myocardial infarction
Figure 3. Strut Coverage at Follow-Up With Respect to Strut Apposition
Blue bars  covered; red bars  uncovered. ISA  incomplete scaffold/
strut apposition; SB  side-branch strut.
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998(15,16). Patients with at least 1 malapposed strut ranged
from 32% to 88% in the same clinical setting (17,18). Our
study observed a rate of acute ISA of 3.5%; and 17 patients
(68%) presented with at least 1 malapposed strut. These
findings suggest that the BVS might have a similar rate of
acute ISA, as compared with metallic-DES.
Figure 2 shows the distribution of the malapposed struts
throughout the BVS length. According to this figure,
malapposed struts were distributed with a particular pattern
and were more frequently located at the 2 edges (especially
at the proximal edge), with few malapposed struts being
located in the central segments of the BVS. This is probably
caused by the placement of the central segment of the BVS
at the site of the minimal lumen area and by the use of
post-dilation balloons (in 56% of patients), shorter than the
length of the scaffold, applied at the central segment of the
BVS. At baseline, 2 of 25 patients presented with scaffold
pattern irregularities resulting in acute strut malapposition.
Both patients were treated with post-dilation balloons
immediately after the BVS implantation. In both cases,
post-dilation balloons were inflated at pressures that re-
sulted in predicted device diameters (according to the
manufacturer’s chart) larger than the recommended limits
for the BVS implantation (3.3 mm for a 3.0-mm nominal
diameter BVS). Scaffold pattern irregularities were located
at the proximal edges and extended over 2 to 4 mm of the
scaffold length. In these images, the number of ISAs were 2
and 5 struts, respectively. Additionally, no intraluminal
mass was observed in these frames.
ISA at 6 months. Malapposed struts of different metallic-
DES ranged from 0% to 15% of the total amount of struts
at 6 months in non–ST-segment elevation myocardial
infarction patients (19–21). In a single study comparing
different metallic-DES, zotarolimus DES presented with
lower rates of malapposed struts (0.0%), as compared with
paclitaxel (0.7%) or sirolimus DES (1.9%) (19). All serial
OCT imaging studies performed with metallic-DES have
found a progressively decreasing amount of malapposed
struts over time (21,22). Unfortunately, at the time of the
present study, no OCT data were available for the everoli-
mus DES at 6-month follow-up.
The healing process of the different metallic-DES is
extremely heterogeneous, with little data being available
with regard to the healing process of malapposed struts.
Serial OCT imaging of sirolimus DES at baseline and
10-month follow-up showed a high rate of persistent
malapposed struts, with 65% of ISA struts observed at
baseline remaining malapposed at follow-up. Late acquired
ISA was observed in 7.3% of malapposed struts at follow-up
(3). Although there are many IVUS studies with serial strut
analysis at baseline and at follow-up, the low sensitivity of
IVUS to assess ISA—when compared with OCT—
challenges the comparability of the results (23). Neverthe-
less, IVUS was able to identify some of the mechanisms dinvolved in the appearance of LAISA with metallic-DES.
Some patients experienced positive remodeling due to vessel
and lumen enlargement without increasing the plaque area.
In these cases, the vessel wall separated from the apposed
strut causing LAISA. This mechanism was more frequently
related to sirolimus DES (24,25) rather than paclitaxel DES
(1,25), everolimus DES (26), or zotarolimus DES (27).
The first generation of the everolimus-eluting BVS (ver-
sion 1.0) presented with more malapposed struts at 6
months than at baseline. A total of 78% of malapposed
struts observed at baseline persisted at 6 months. Late
acquired ISA was observed in 1.0% of the total amount of
struts and represented 16% of the total amount of ISA at
follow-up (8). The most plausible explanation for this
phenomenon was the loss in scaffold area observed during
the first 6 months, when the BVS version 1.0 had a
premature loss of its radial force and structural continuity
(10). This phenomenon caused the displacement of the
scaffold into the lumen and probably delayed the healing of
previously (baseline) malapposed struts. Likewise, this prob-
ably caused the appearance of new malapposed struts at
follow-up that were apposed at baseline (LAISA). As
assessed by IVUS (8), positive remodeling was not observed
with the BVS (version 1.0), unlike what was previously
reported in DES.
In our study, with the new generation of BVS (version
1.1), the percentage of malapposed struts at 6-month
follow-up was inferior to that at baseline (0.8% vs. 3.5%,
respectively; p  0.01). Only 15% of the malapposed struts
at baseline persisted at follow-up. Late acquired ISA was
observed in 5 struts (1.0%) in 2 patients and represented
16% of malapposed struts at follow-up. The mechanism
owing to LAISA in these 2 patients was the emergence of
scaffold pattern irregularities not observed at baseline. Scaf-
fold pattern irregularities were extended over 4 mm
throughout the length of the BVS and were mainly located
at the proximal edge. The IVUS analysis showed the
absence of positive remodeling at the site of the external
elastic membrane in those patients (data not shown).
Figures 4 and 5 show matched OCT images from baseline
to 6-month follow-up of the 2 patients with LAISA caused
by the emergence of scaffold pattern irregularities. Al-
though scaffold pattern irregularities were not observed in
any of those patients at baseline, it is remarkable that the
respective patients had been treated with post-dilation
with balloons that over-stretched the BVS to larger
diameters than the recommended maximum device di-
ameter of 3.3 mm.
The matched images of the 7 struts with acute ISA due
to acute scaffold pattern irregularities (at baseline) evolved to
ISA  covered (3 struts) and to ISA  uncovered (4 struts)
at 6 months. None of the cases were related to LAISA.
Strut coverage at 6-month follow-up. Strut coverage ofifferent metallic-DES is extremely heterogeneous. At 6
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999months, sirolimus DES presented with a rate of uncovered
struts from 8.7% to 15.0% (19–22). Uncovered struts with
paclitaxel DES ranged from 2.7% to 5.0% (19,20), and
zotarolimus DES presented with 0% of uncovered struts in
a single report (19).
In our study, with the new generation of BVS (version
1.1), a total of 1.6% of struts were uncovered at 6-month
follow-up. The distribution of uncovered struts throughout
the BVS length did not show any particular pattern (Fig. 2).
However, uncovered struts at follow-up were relatively more
frequently found in struts that at baseline were ISA and SB
struts rather than apposed struts. Similar results have been
obtained with serial OCT imaging of sirolimus DES. Ozaki
Figure 4. Late Acquired ISA
Consecutive, matched OCT images at baseline (A to E) and 6 months (A‘ to E
fold pattern is regular. B, C, and D show 1 apposed strut at baseline (arrows)
pattern irregularities. Abbreviations as in Figure 2.
Figure 5. Late Acquired ISA With Attached Intraluminal Masses
Consecutive, matched OCT images at baseline (A to F) and 6-month follow-up
device diameter. The OCT images show all struts are apposed to the vessel wa
pattern irregularities resulting in strut malapposition and lack of tissue coverag
attached to the malapposed and uncovered struts. Abbreviations as in Figure 2.et al. (3) found a higher percentage of uncovered struts, at
10-month follow-up, in struts that were malapposed at
baseline (65.4%) as compared with struts that were apposed
(8.6%). The first generation of everolimus-eluting BVS
(version 1.0) presented with 1.0% of uncovered struts at
6-month follow-up (8). Although the rate of ISA at 6
months was relatively high, uncovered struts were not
commonly found. Moreover, the mean neointimal hyper-
plasia area was statistically higher with the BVS version 1.0
than with the BVS version 1.1 (10). There is no clear
explanation for these findings. One hypothesis is that the
advanced resorption state and the strut appearance changes
observed with the BVS version 1.0 at 6 months as compared
patient treated with excessive post-dilation (3.4 mm). At baseline, the scaf-
t follow-up evolved to acquired malapposed strut (arrows) due to scaffold
o F‘). At baseline, the scaffold was post-dilated up to 3.4 mm of predicted
out scaffold pattern irregularities. At 6 months, the scaffold presents with
Irregular intraluminal masses (arrows) with mild shadowing behind are‘) of 1
that a(A‘ t
ll with
e (*).
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1000with the BVS 1.1 could trigger a higher neointimal response
and strut coverage.
Intraluminal masses at 6-month follow-up. Lack of neointi-
mal coverage of different DES was proposed as the best
predictor of late stent thrombosis in pathological studies (6).
However, although sirolimus DES presented with a higher
percentage of uncovered struts compared with paclitaxel
DES, thrombi were more frequently found with paclitaxel
DES (20). This observation supports the concept of a
multicausal pathogenesis of late stent thrombosis, including
malapposition, expansive vessel remodeling, and other fac-
tors that can initiate thrombus formation (28,29). Due to its
high resolution, OCT is able to visualize, with great detail,
many of the proposed predictors of late stent thrombosis in
vivo (3,30). With sirolimus DES, Ozaki et al. (3) found
4.1% of frames with thrombi at 10-month follow-up;
thrombi were more frequently observed in frames with ISA
than in those without this feature (21% vs. 2%, respectively,
p  0.01). Our study found 14 cross-sections (2.9%) in 6
atients (24%) containing intraluminal masses at 6-month
ollow-up. Intraluminal masses were more frequently ob-
erved in cross-sections with ISA than without (39% vs. 2%;
 0.01) and in cross-sections with uncovered struts than
ithout (13% vs. 2%; p  0.01), supporting that malappo-
sition and absence of coverage can initiate thrombosis.
However, whether this is of clinical importance needs to be
further investigated. Figure 5 shows intraluminal masses
attached to malapposed and uncovered struts in 1 patient
with acquired scaffold pattern irregularities and LAISA at 6
months.
Clinical implications. In our study, the new generation of
BVS presented with a lower rate of ISA, uncovered struts,
and intraluminal masses as compared with sirolimus DES at
6-month follow-up. The polymeric nature of this new
technology, however, could render it susceptible to iatro-
genically induced scaffold pattern irregularities. These can
lead to ISA and lack of strut coverage at 6-month follow-up.
The 5 cases reported in our study were treated with
aggressive post-dilations, probably resulting in overstretch-
ing of the scaffold at the time of the implantation. A third
generation of the device is intended to raise the limit of
deployment of the 3.0-mm nominal diameter device to 3.8
mm. Nevertheless, the previous generation of the BVS
(version 1.0) showed a complete resorption of its compo-
nents at 2-year follow-up without any malapposed or
uncovered struts (7). Therefore, in this case, the treatment
with dual antiplatelet therapy can become unnecessary. It is,
however, currently uncertain whether the new generation of
the BVS (version 1.1) will exhibit similar resorption char-
acteristics at 2 years.
Study limitations. The first limitation of the present study is
the limited number of patients. However, our report is 1 of
the largest OCT studies with serial imaging of the same
intracoronary device at baseline and at follow-up. Thesecond limitation is the lack of statistical adjustment for
clinical and anatomic covariables. The clustering essence of
the OCT data (patient level, stent level, frame level, and
strut level) needs a multilevel regression analysis not applied
in our study. Moreover, the different OCT pullback speed,
frame/rate, and quality of the image of the 2 OCT systems
used in the present study hamper the matching of cross-
sections between baseline and follow-up. A total of 12
cross-sections were unmatchable from baseline to follow-up
or vice versa: 8 cross-sections were imaged with the M3
OCT system and 4 cross-sections were imaged with the C7
OCT system in both baseline and follow-up. Finally, the
last limitation is the lack of results at very-long-term
follow-up. The extrapolation of the 2-year follow-up results
observed with the first generation of BVS (version 1.0) with
the new generation of BVS (version 1.1) is purely specula-
tive. However, all patients included in the ABSORB cohort
B study will be reinvestigated at 2-year follow-up with
invasive imaging techniques.
Conclusions
The new generation of BVS exhibited a low rate of acute,
persistent, and late acquired incomplete strut/scaffold
malapposition as well as uncovered struts. At baseline and
follow-up, malapposed and SB struts were related to a lack
of tissue coverage at 6 months. Scaffold pattern irregularities
were the only cause observed in our study of late acquired
malapposed struts and were also related to a lack of tissue
coverage. Attached intraluminal masses occurred more fre-
quently in malapposed and uncovered struts at 6 months. A
more careful device implantation, with appropriate sizing of
the vessel and respecting the deployment limits of inflation,
will reduce the rates of acute ISA and scaffold pattern
irregularities and, therefore, could circumvent most of the
ISA, uncovered struts, and intraluminal masses observed at
midterm follow-up.
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